Cmic CRO Of Japan To Buy Drug-Production Plant From Daiichi Sankyo
This article was originally published in PharmAsia News
Japan's Cmic plans to buy a Daiichi Sankyo manufacturing plant to produce oral and injection drug formulations. The contract research organization is expanding its business beyond conducting clinical trials to producing products for pharmaceutical companies, including Daiichi Sankyo. The acquisition of the Daiichi Sankyo Propharma plant in Japan is expected to give Cmic the capacity to produce 1.5 billion tablets and 3 million vials of drugs a year. The purchase price still has to be settled between the two firms. (Click here for more - a subscription may be required
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.